Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: CRIS
- CUSIP: 23126910
- Previous Close: $2.68
- 50 Day Moving Average: $2.85
- 200 Day Moving Average: $2.63
- 52-Week Range: $1.34 - $3.72
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.66
- P/E Growth: 0.00
- Market Cap: $376.67M
- Outstanding Shares: 140,549,000
- Beta: 1.89
- Net Margins: -861.64%
- Return on Equity: -99.45%
- Return on Assets: -63.44%
Companies Related to Curis:
- Debt-to-Equity Ratio: 0.42%
- Current Ratio: 4.54%
- Quick Ratio: 4.54%
What is Curis' stock symbol?
Curis trades on the NASDAQ under the ticker symbol "CRIS."
Where is Curis' stock going? Where will Curis' stock price be in 2017?
6 equities research analysts have issued 12 month price targets for Curis' stock. Their predictions range from $3.00 to $7.00. On average, they expect Curis' stock price to reach $5.50 in the next twelve months.
When will Curis announce their earnings?
Curis is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Curis stock?
Curis' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (10.49%), State Street Corp (1.18%), Marshall Wace LLP (0.31%), Renaissance Technologies LLC (0.26%), Focused Wealth Management Inc (0.13%) and Metropolitan Life Insurance Co. NY (0.06%). Company insiders that own Curis stock include Daniel R Passeri, Discovery Technologie Aurigene, Kenneth I Kaitin and Martyn D Greenacre.
Who sold Curis stock? Who is selling Curis stock?
Curis' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP and Focused Wealth Management Inc. Company insiders that have sold Curis stock in the last year include Kenneth I Kaitin and Martyn D Greenacre.
Who bought Curis stock? Who is buying Curis stock?
Curis' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, State Street Corp, Two Sigma Investments LP, Fred Alger Management Inc., Oxford Asset Management, A.R.T. Advisors LLC, Dynamic Technology Lab Private Ltd and Metropolitan Life Insurance Co. NY.
How do I buy Curis stock?
Shares of Curis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Curis stock cost?
One share of Curis stock can currently be purchased for approximately $2.68.